97 related articles for article (PubMed ID: 26026911)
41. Piperlongumine induces gastric cancer cell apoptosis and G2/M cell cycle arrest both in vitro and in vivo.
Duan C; Zhang B; Deng C; Cao Y; Zhou F; Wu L; Chen M; Shen S; Xu G; Zhang S; Duan G; Yan H; Zou X
Tumour Biol; 2016 Aug; 37(8):10793-804. PubMed ID: 26874726
[TBL] [Abstract][Full Text] [Related]
42. Leukemia-Associated Mutations in Nucleophosmin Alter Recognition by CRM1: Molecular Basis of Aberrant Transport.
Arregi I; Falces J; Olazabal-Herrero A; Alonso-Mariño M; Taneva SG; Rodríguez JA; Urbaneja MA; Bañuelos S
PLoS One; 2015; 10(6):e0130610. PubMed ID: 26091065
[TBL] [Abstract][Full Text] [Related]
43. Novel reversible selective inhibitor of CRM1 for targeted therapy in ovarian cancer.
Liu X; Chong Y; Liu H; Han Y; Niu M
J Ovarian Res; 2015 Jun; 8():35. PubMed ID: 26055813
[TBL] [Abstract][Full Text] [Related]
44. Expression, function, and targeting of the nuclear exporter chromosome region maintenance 1 (CRM1) protein.
Ishizawa J; Kojima K; Hail N; Tabe Y; Andreeff M
Pharmacol Ther; 2015 Sep; 153():25-35. PubMed ID: 26048327
[TBL] [Abstract][Full Text] [Related]
45. Piperlongumine Induces Reactive Oxygen Species (ROS)-Dependent Downregulation of Specificity Protein Transcription Factors.
Karki K; Hedrick E; Kasiappan R; Jin UH; Safe S
Cancer Prev Res (Phila); 2017 Aug; 10(8):467-477. PubMed ID: 28673967
[TBL] [Abstract][Full Text] [Related]
46. Piperlongumine inhibits gastric cancer cells via suppression of the JAK1,2/STAT3 signaling pathway.
Song B; Zhan H; Bian Q; Gu J
Mol Med Rep; 2016 May; 13(5):4475-80. PubMed ID: 27053336
[TBL] [Abstract][Full Text] [Related]
47. Piperlongumine as a direct TrxR1 inhibitor with suppressive activity against gastric cancer.
Zou P; Xia Y; Ji J; Chen W; Zhang J; Chen X; Rajamanickam V; Chen G; Wang Z; Chen L; Wang Y; Yang S; Liang G
Cancer Lett; 2016 May; 375(1):114-126. PubMed ID: 26963494
[TBL] [Abstract][Full Text] [Related]
48. Piperlongumine exerts cytotoxic effects against cancer cells with mutant p53 proteins at least in part by restoring the biological functions of the tumor suppressor.
Basak D; Punganuru SR; Srivenugopal KS
Int J Oncol; 2016 Apr; 48(4):1426-36. PubMed ID: 26848023
[TBL] [Abstract][Full Text] [Related]
49. Piperlongumine Suppresses Growth and Sensitizes Pancreatic Tumors to Gemcitabine in a Xenograft Mouse Model by Modulating the NF-kappa B Pathway.
Wang Y; Wu X; Zhou Y; Jiang H; Pan S; Sun B
Cancer Prev Res (Phila); 2016 Mar; 9(3):234-44. PubMed ID: 26667450
[TBL] [Abstract][Full Text] [Related]
50. Auranofin induces apoptosis by ROS-mediated ER stress and mitochondrial dysfunction and displayed synergistic lethality with piperlongumine in gastric cancer.
Zou P; Chen M; Ji J; Chen W; Chen X; Ying S; Zhang J; Zhang Z; Liu Z; Yang S; Liang G
Oncotarget; 2015 Nov; 6(34):36505-21. PubMed ID: 26431378
[TBL] [Abstract][Full Text] [Related]
51. Piperlongumine induces apoptosis and autophagy in human lung cancer cells through inhibition of PI3K/Akt/mTOR pathway.
Wang F; Mao Y; You Q; Hua D; Cai D
Int J Immunopathol Pharmacol; 2015 Sep; 28(3):362-73. PubMed ID: 26246196
[TBL] [Abstract][Full Text] [Related]
52. Synthesis of piperlongumine analogues and discovery of nuclear factor erythroid 2-related factor 2 (Nrf2) activators as potential neuroprotective agents.
Peng S; Zhang B; Meng X; Yao J; Fang J
J Med Chem; 2015 Jul; 58(13):5242-55. PubMed ID: 26079183
[TBL] [Abstract][Full Text] [Related]
53. Effect of piperlongumine on drug resistance reversal in human retinoblastoma HXO-RB44/VCR and SO-Rb50/CBP cell lines.
Wang XQ; Wang YC; Guo YT; Tang X
Int J Clin Exp Pathol; 2015; 8(3):2525-34. PubMed ID: 26045758
[TBL] [Abstract][Full Text] [Related]
54. Three cardiovirus Leader proteins equivalently inhibit four different nucleocytoplasmic trafficking pathways.
Ciomperlik JJ; Basta HA; Palmenberg AC
Virology; 2015 Oct; 484():194-202. PubMed ID: 26115166
[TBL] [Abstract][Full Text] [Related]
55. The nuclear export protein exportin-1 in solid malignant tumours: From biology to clinical trials.
Lai C; Xu L; Dai S
Clin Transl Med; 2024 May; 14(5):e1684. PubMed ID: 38783482
[TBL] [Abstract][Full Text] [Related]
56. The Antitumor Activity of Piplartine: A Review.
Duarte ABS; Gomes RC; Nunes VRV; Gonçalves JCR; Correia CA; Dos Santos AZG; de Sousa DP
Pharmaceuticals (Basel); 2023 Sep; 16(9):. PubMed ID: 37765054
[TBL] [Abstract][Full Text] [Related]
57. Molecular Modeling and In Vitro Evaluation of Piplartine Analogs against Oral Squamous Cell Carcinoma.
Silva RHN; Machado TQ; da Fonseca ACC; Tejera E; Perez-Castillo Y; Robbs BK; de Sousa DP
Molecules; 2023 Feb; 28(4):. PubMed ID: 36838660
[TBL] [Abstract][Full Text] [Related]
58. The promising potential of piperlongumine as an emerging therapeutics for cancer.
Parama D; Rana V; Girisa S; Verma E; Daimary UD; Thakur KK; Kumar A; Kunnumakkara AB
Explor Target Antitumor Ther; 2021; 2(4):323-354. PubMed ID: 36046754
[TBL] [Abstract][Full Text] [Related]
59. Peppers: A "Hot" Natural Source for Antitumor Compounds.
Cunha MR; Tavares MT; Fernandes TB; Parise-Filho R
Molecules; 2021 Mar; 26(6):. PubMed ID: 33802144
[No Abstract] [Full Text] [Related]
60. Secondary Metabolic Profile as a Tool for Distinction and Characterization of Cultivars of Black Pepper (
Barata LM; Andrade EH; Ramos AR; de Lemos OF; Setzer WN; Byler KG; Maia JGS; da Silva JKR
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33477389
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
